Research Paper Volume 12, Issue 14 pp 14556—14568
TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy
Figure 4. TIMER database analysis shows the abundance of six tumor-infiltrating immune cell types in TP53 wild-type or mutated lung adenocarcinoma tumor samples. * denotes P < 0.05; ** denotes P < 0.01.